SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is attracting significant attention as community members analyze its resilience amidst geopolitical tensions and supply chain complexities while weighing the impact of its major Small Modular Reactor (SMR) contracts and defense partnerships. Investors are actively discussing the company's long-term transformation, focusing on whether current volatility provides an optimal entry point or signals broader headwinds for its commercial aerospace engine business.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as investors focus on its role in building decentralized AI infrastructure, with significant community excitement surrounding its potential as a long-term asset akin to early-stage growth plays. Discussions are heavily focused on the project's subnet ecosystem, institutional interest, and the strategy of staking as a means to accumulate value despite broader market volatility.

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX's Nasdaq debut has triggered intense debate, with the stock drawing record trading volumes and massive institutional inflows despite significant concerns over its lack of profitability and sky-high valuation. While bullish investors view the company as a transformative leader in space and AI infrastructure, the community remains divided as traders focus on the upcoming options chain launch and the technical implications of its massive market capitalization.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

The Tema Space Innovators ETF ($NASA) is experiencing high volatility as investors navigate the highly anticipated SpaceX IPO and broader sector re-rating. Community members are actively debating whether the current pullback represents a strategic buying opportunity before potential index inclusion or a liquidity-driven flush as capital rotates toward the direct SpaceX listing.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is experiencing significant volatility as investors weigh disappointing monthly sales data against anticipated long-term milestones like J-code reimbursement and potential European market expansion. The community remains deeply divided, with many shareholders dismissing the price drop as algorithmic manipulation and short-term weakness while expressing frustration over management's lack of transparency regarding recent executive departures.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and downward pressure despite reporting strong quarterly revenue, leaving investors divided between those focused on the potential of the Elevidys gene therapy pipeline and those frustrated by a perceived lack of management action on the share price. The community is actively discussing potential leadership transitions, rumors of a strategic reorganization or buyout, and the impact of broader biotech sector headwinds on the symbol's recent performance.

Strategy, Inc. is a Bitcoin Treasury company. The firm has adopted Bitcoin as a primary treasury reserve asset. It uses proceeds from equity and debt financing, as well as cash flows from operations, to strategically accumulate Bitcoin and advocate for its role as digital capital. Its treasury strategy is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. It provides industry AI-powered enterprise analytics software. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heavy volatility as investors debate the impact of ongoing share dilution and the company's aggressive Bitcoin acquisition strategy amid a broader crypto market downturn. The community remains deeply polarized, with active discussion focusing on the sustainability of the firm's balance sheet, the potential for institutional hedging, and the contrast between Bitcoin-proxy plays and emerging opportunities in the AI and space sectors.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF is trending as investors grapple with escalating volatility stemming from the ongoing conflict with Iran and concerns regarding a potential regional ground incursion. The broader market sentiment is reacting to community anxiety over rising energy costs, potential inflation spikes, and the sustainability of the current AI-driven equity valuations.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors weigh potential steel demand from industrial data center builds against ongoing speculation regarding a strategic partnership with POSCO. Community sentiment remains polarized, with some traders monitoring high options volume and potential short squeezes, while others express frustration over management's debt and long-term capital efficiency.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh strong IBSRELA revenue growth and potential clinical pipeline expansion against ongoing concerns regarding the CMS bundling dispute and future profitability milestones. The community is actively debating the company's valuation relative to its peers and speculating on the possibility of an acquisition or strategic partnership as the firm matures into a self-sustaining commercial operation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight...

Can Gilead Sciences HIV Franchise Drive Long-Term Growth?

Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study

Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV...

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gileads Trodelvy (sacituzumab govitecan-hziy) in combination with KEYTRUDA (pembrolizumab...

Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now?

Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now...

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. This press release features multimedia...

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Bearish Sentiment

Track GILD stock price, charts, news and real-time market activity on Stocktwits. Join the GILD message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Gilead Sciences, Inc stock.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$6.94	--	--	N/A
Q1 '26	$1.91	$2.03	6.31%	BEAT
Q4 '25	$1.81	$1.86	2.76%	BEAT
Q3 '25	$2.13	$2.47	15.85%	BEAT
Q2 '25	$1.96	$2.01	2.55%	BEAT

GILDGilead Sciences, Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest GILD News